Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its target price boosted by analysts at Robert W. Baird from $67.00 to $132.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 66.60% from the company’s previous close.

Other research analysts also recently issued research reports about the company. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Wedbush boosted their price objective on Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, Truist Financial lifted their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $105.89.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $79.23 on Tuesday. The stock has a fifty day moving average price of $49.17 and a two-hundred day moving average price of $41.17. The firm has a market capitalization of $3.42 billion, a P/E ratio of -22.77 and a beta of 1.56. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $84.86.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Fairmount Funds Management LLC lifted its position in Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares in the last quarter. Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the last quarter. Finally, TCG Crossover Management LLC raised its stake in shares of Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.